Quarterly Report (10-q)

0.01false2021-12-31Q3--12-3110.0100013935840001393584us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2021-01-012021-09-300001393584amwl:CcawJvLlcMember2022-07-012022-09-300001393584us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001393584amwl:CcawJvLlcMember2021-07-012021-09-300001393584amwl:SilverCloudHealthHoldingsIncMember2022-07-012022-09-300001393584amwl:VisitsMember2022-07-012022-09-300001393584amwl:PlatformSubscriptionMember2022-07-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-03-310001393584us-gaap:ParentMember2021-12-310001393584amwl:ConversaHealthIncMember2021-08-090001393584us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:RestrictedStockUnitsRSUMember2021-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2020-12-310001393584amwl:NtnMemberMember2021-07-012021-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001393584amwl:VisitsMember2022-01-012022-09-300001393584us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001393584us-gaap:CommonStockMember2022-01-012022-03-310001393584us-gaap:CommonStockMember2022-07-012022-09-3000013935842020-12-310001393584us-gaap:NoncontrollingInterestMemberamwl:NtnMemberMember2021-12-310001393584amwl:NtnMemberMember2022-01-012022-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001393584us-gaap:RestrictedStockMembersrt:MaximumMember2022-01-012022-09-300001393584us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-3100013935842021-01-012021-03-310001393584us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001393584us-gaap:CommonStockMember2020-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2021-12-310001393584us-gaap:AccountingStandardsUpdate201912Member2022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001393584us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001393584us-gaap:NoncontrollingInterestMember2021-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-09-300001393584us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584us-gaap:ContractBasedIntangibleAssetsMember2021-12-310001393584us-gaap:CostOfSalesMember2021-01-012021-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001393584us-gaap:TreasuryStockMember2020-12-310001393584us-gaap:CommonStockMember2021-07-012021-09-300001393584us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000013935842021-12-310001393584amwl:CcawJvLlcMember2020-12-310001393584us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584srt:ManagementMembersrt:MaximumMemberus-gaap:PerformanceSharesMember2022-09-300001393584us-gaap:CommonStockMember2021-03-310001393584us-gaap:ParentMember2022-06-3000013935842021-07-012021-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-03-3100013935842022-03-310001393584us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2021-07-012021-09-300001393584us-gaap:RestrictedStockMembersrt:MinimumMember2022-01-012022-09-300001393584amwl:ConversaHealthIncMember2022-01-012022-01-310001393584us-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:CommonClassBMember2022-01-012022-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-09-300001393584us-gaap:CommonStockMember2022-03-310001393584amwl:PlatformSubscriptionMember2021-07-012021-09-300001393584srt:MaximumMemberamwl:NtnMemberMember2016-01-010001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-12-310001393584us-gaap:ParentMember2020-12-310001393584us-gaap:RetainedEarningsAppropriatedMember2021-01-012021-03-310001393584us-gaap:TechnologyBasedIntangibleAssetsMemberamwl:SilverCloudHealthHoldingsIncMember2021-08-272021-08-270001393584us-gaap:CustomerRelationshipsMemberamwl:SilverCloudHealthHoldingsIncMember2021-08-272021-08-270001393584us-gaap:AdditionalPaidInCapitalMember2022-06-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-07-012021-09-3000013935842022-01-012022-09-300001393584us-gaap:CommonClassCMember2022-10-310001393584us-gaap:CustomerRelationshipsMember2021-12-310001393584amwl:ConversaHealthIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-08-092021-08-090001393584us-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2021-12-310001393584us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001393584us-gaap:PendingLitigationMember2021-12-310001393584amwl:ConversaHealthIncMemberus-gaap:TradeNamesMember2021-08-092021-08-0900013935842022-06-300001393584us-gaap:NoncontrollingInterestMemberamwl:NtnMemberMember2022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-06-300001393584us-gaap:CommonClassBMember2022-07-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001393584us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001393584amwl:ConversaHealthIncMember2021-08-092021-08-090001393584us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-07-012022-09-300001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-09-300001393584us-gaap:AccountsReceivableMember2022-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001393584amwl:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2022-01-012022-09-300001393584srt:MinimumMemberamwl:NtnMemberMember2016-01-010001393584us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584amwl:ClevelandClinicMember2021-07-012021-09-300001393584us-gaap:ParentMember2021-03-310001393584us-gaap:AdditionalPaidInCapitalMember2021-09-300001393584us-gaap:IndemnificationGuaranteeMember2022-01-012022-09-300001393584us-gaap:TreasuryStockMember2021-01-012021-03-310001393584amwl:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:RestrictedStockUnitsRSUMember2022-09-300001393584us-gaap:PerformanceSharesMember2022-01-012022-09-300001393584us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001393584us-gaap:AccountingStandardsUpdate201613Member2022-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001393584amwl:ClevelandClinicMember2021-01-012021-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001393584us-gaap:NoncontrollingInterestMember2021-12-310001393584us-gaap:TradeNamesMember2021-01-012021-12-310001393584us-gaap:ParentMember2021-04-012021-06-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001393584us-gaap:ParentMember2022-07-012022-09-300001393584us-gaap:ParentMember2021-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-01-012022-03-310001393584amwl:ClevelandClinicMember2022-07-012022-09-300001393584us-gaap:AccountingStandardsUpdate202108Member2022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2021-12-310001393584us-gaap:CommonStockMember2021-01-012021-03-310001393584us-gaap:ContractBasedIntangibleAssetsMember2022-09-300001393584us-gaap:CustomerRelationshipsMemberamwl:ConversaHealthIncMember2021-08-092021-08-090001393584us-gaap:CostOfSalesMember2022-07-012022-09-300001393584us-gaap:CommonStockMember2021-06-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2021-01-012021-09-300001393584amwl:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2021-01-012021-09-3000013935842021-09-300001393584us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584amwl:PlatformSubscriptionMember2022-01-012022-09-3000013935842022-01-012022-03-310001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2021-01-012021-12-310001393584us-gaap:NoncontrollingInterestMember2021-06-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-04-132022-04-130001393584us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:AdditionalPaidInCapitalMember2020-12-310001393584us-gaap:CommonClassCMember2021-12-310001393584us-gaap:CommonStockMember2022-04-012022-06-300001393584amwl:CcawJvLlcMember2022-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-07-012021-09-300001393584us-gaap:AdditionalPaidInCapitalMember2021-06-300001393584amwl:UnvestedRestrictedStockMember2022-07-012022-09-300001393584us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001393584us-gaap:ContractBasedIntangibleAssetsMember2021-01-012021-12-310001393584us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001393584us-gaap:PerformanceSharesMember2021-01-012021-09-300001393584us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-09-300001393584us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001393584us-gaap:ParentMember2022-03-310001393584us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-310001393584us-gaap:CommonClassAMember2022-09-300001393584us-gaap:PerformanceSharesMember2022-09-3000013935842021-03-3100013935842021-06-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2022-01-012022-09-300001393584us-gaap:NoncontrollingInterestMember2021-03-310001393584us-gaap:CommonClassAMemberamwl:SilverCloudHealthHoldingsIncMember2021-08-272021-08-270001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-01-012020-12-3100013935842021-04-012021-06-300001393584us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001393584us-gaap:CommonClassBMember2022-09-300001393584us-gaap:CommonClassAMember2021-12-310001393584amwl:VisitsMember2021-07-012021-09-300001393584amwl:UnvestedRestrictedStockMember2021-07-012021-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-09-300001393584us-gaap:CostOfSalesMember2022-01-012022-09-300001393584srt:MaximumMemberamwl:CoChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember2022-09-300001393584amwl:CcawJvLlcMember2022-01-012022-09-300001393584amwl:NtnMemberMember2022-07-012022-09-300001393584us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001393584us-gaap:CommonClassCMember2022-01-012022-09-3000013935842022-07-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-09-3000013935842022-01-012021-12-310001393584us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001393584us-gaap:ContractBasedIntangibleAssetsMember2022-01-012022-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-04-012021-06-300001393584amwl:AnthemIncMember2021-02-012021-02-280001393584amwl:ClevelandClinicMember2022-01-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-04-012022-06-300001393584us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584amwl:UnvestedRestrictedStockMember2021-01-012021-09-300001393584srt:MaximumMember2022-01-012022-09-300001393584us-gaap:ParentMember2021-06-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001393584us-gaap:CustomerRelationshipsMember2021-01-012021-12-310001393584us-gaap:CommonStockMember2021-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001393584amwl:SilverCloudHealthHoldingsIncMemberus-gaap:CommonClassAMember2022-05-112022-05-110001393584us-gaap:TradeNamesMember2021-12-310001393584amwl:SilverCloudHealthHoldingsIncMember2021-08-272021-08-270001393584us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2022-09-3000013935842021-01-012021-09-300001393584us-gaap:CommonStockMember2022-06-300001393584us-gaap:IndemnificationGuaranteeMember2021-01-012021-12-3100013935842022-09-300001393584us-gaap:ParentMember2022-09-3000013935842022-04-012022-06-300001393584amwl:ClevelandClinicMember2022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001393584us-gaap:OtherAssetsMember2022-09-300001393584amwl:SilverCloudHealthHoldingsIncMemberus-gaap:TradeNamesMember2021-08-272021-08-270001393584us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001393584us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-3000013935842022-10-012022-09-300001393584us-gaap:CommonStockMemberamwl:EquityAwardPlanMember2022-09-300001393584amwl:PlatformSubscriptionMember2021-01-012021-09-300001393584us-gaap:CommonClassCMember2022-09-300001393584us-gaap:ParentMember2022-01-012022-03-310001393584us-gaap:ParentMember2021-01-012021-03-310001393584amwl:CoChiefExecutiveOfficerMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300001393584amwl:OthersMember2021-07-012021-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-07-012021-09-300001393584us-gaap:NoncontrollingInterestMember2022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2021-03-310001393584us-gaap:TradeNamesMember2022-01-012022-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-300001393584us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001393584srt:ManagementMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300001393584amwl:UnvestedRestrictedStockMember2022-01-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2022-03-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001393584amwl:VisitsMember2021-01-012021-09-300001393584us-gaap:CommonStockMember2022-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001393584us-gaap:PendingLitigationMember2022-09-300001393584amwl:UnvestedPerformanceMarketBasedStockUnitsMember2022-07-012022-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001393584us-gaap:CommonStockMemberamwl:EquityAwardPlanMember2022-01-012022-09-300001393584us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-07-012022-09-300001393584amwl:PhilipsHoldingUsaIncMember2022-06-012022-06-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001393584us-gaap:CostOfSalesMember2021-07-012021-09-300001393584amwl:ConversaHealthIncMemberus-gaap:CommonClassAMember2022-01-012022-09-300001393584us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001393584amwl:ConversaHealthIncMemberus-gaap:CommonClassAMember2022-01-012022-03-310001393584us-gaap:NoncontrollingInterestMember2020-12-310001393584amwl:OthersMember2021-01-012021-09-300001393584amwl:ConversaHealthIncMemberus-gaap:CommonClassAMember2021-08-092021-08-090001393584us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001393584us-gaap:RestrictedStockMember2021-01-012021-09-300001393584amwl:CcawJvLlcMember2021-12-310001393584amwl:SilverCloudHealthHoldingsIncMember2021-08-270001393584us-gaap:NoncontrollingInterestMember2022-03-310001393584us-gaap:RetainedEarningsAppropriatedMember2022-06-300001393584us-gaap:CommonClassBMember2021-12-310001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-310001393584us-gaap:TradeNamesMember2022-09-300001393584amwl:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001393584amwl:TwoThousandAndTwentyEquityIncentivePlanMember2022-01-012022-09-300001393584amwl:CcacvJvLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-09-300001393584us-gaap:ParentMember2022-04-012022-06-300001393584us-gaap:CommonClassBMember2022-10-310001393584amwl:CcawJvLlcMember2020-01-012020-12-310001393584us-gaap:NoncontrollingInterestMember2022-06-300001393584us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001393584us-gaap:CommonClassAMember2022-10-310001393584amwl:OthersMember2022-07-012022-09-300001393584us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001393584us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001393584us-gaap:ParentMember2021-07-012021-09-300001393584us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001393584us-gaap:AdditionalPaidInCapitalMember2022-03-310001393584amwl:NtnMemberMember2021-01-012021-09-300001393584amwl:RelatedPartyCustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001393584us-gaap:RestrictedStockMember2022-01-012022-09-300001393584us-gaap:RetainedEarningsAppropriatedMember2021-09-300001393584us-gaap:CustomerRelationshipsMember2022-01-012022-09-300001393584amwl:CcawJvLlcMember2021-01-012021-09-300001393584us-gaap:CustomerRelationshipsMember2022-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001393584us-gaap:CommonClassAMember2022-01-012022-09-300001393584us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001393584amwl:ClevelandClinicMember2021-12-310001393584us-gaap:CommonStockMember2021-12-310001393584amwl:OthersMember2022-01-012022-09-300001393584us-gaap:CommonStockMember2021-04-012021-06-300001393584us-gaap:AccountsReceivableMember2021-12-310001393584us-gaap:OtherAssetsMember2021-12-3100013935842021-01-012021-12-310001393584us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-09-30amwl:Segmentxbrli:purexbrli:sharesamwl:Trancheiso4217:USDxbrli:sharesiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39515

American Well Corporation

(Exact name of registrant as specified in its charter)


Delaware	20-5009396
(State of incorporation)	(I.R.S. Employer Identification Number)

75 State Street, 26th Floor

Boston, MA 02109

(Address of registrant’s principal executive offices)

(617) 204-3500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value of $0.01 per share	AMWL	The New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☐

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 31, 2022, the number of shares of the registrant’s Class A common stock outstanding was 242,463,684, the number of shares of the registrant’s Class B common stock outstanding was 27,390,397 and the number of shares of the registrant’s Class C common stock outstanding was 5,555,555.

American Well Corporation

QUARTERLY REPORT ON FORM 10-Q

For the period ended September 30, 2022

TABLE OF CONTENTS


		Page
PART I	Financial Information	3
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheet as of September 30, 2022 (unaudited) and December 31, 2021	3
	Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2022 and 2021	4
	Condensed Consolidated Statement of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2022 and 2021	5
	Condensed Consolidated Statement of Cash Flows (unaudited) for the nine months ended September 30, 2022 and 2021	7
	Notes to the Unaudited Condensed Consolidated Financial Statements	8
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35
PART II	Other Information	37
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	38
Item 5.	Other Information	38
Item 6.	Exhibits	38

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)


	September 30, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	332,601		$	746,416
Investments		249,008			—
Accounts receivable ($164 and $2,054, from related parties and net of allowances of $1,568 and $1,809, respectively)		45,730			51,375
Inventories		7,969			7,530
Deferred contract acquisition costs		1,338			1,697
Prepaid expenses and other current assets		20,598			20,278
Total current assets		657,244			827,296
Restricted cash		795			795
Property and equipment, net		1,079			2,235
Goodwill		425,196			442,761
Intangible assets, net		127,291			152,409
Operating lease right-of-use asset		14,412			16,422
Deferred contract acquisition costs, net of current portion		3,064			2,028
Other assets		1,920			1,722
Investment in minority owned joint venture		773			168
Total assets	$	1,231,774		$	1,445,836
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	6,175		$	12,156
Accrued expenses and other current liabilities		45,181			58,711
Operating lease liability, current		3,623			1,918
Deferred revenue ($338 and $1,860 from related parties, respectively)		50,151			68,841
Total current liabilities		105,130			141,626
Other long-term liabilities		2,673			5,136
Contingent consideration liabilities, net of current portion		—			16,450
Operating lease liability, net of current portion		12,208			14,694
Deferred revenue, net of current portion ($13 and $22 from related parties, respectively)		6,914			7,055
Total liabilities		126,925			184,961
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of September 30, 2022 and as of December 31, 2021		—			—
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 242,304,366 and 229,402,453 shares issued and outstanding, respectively; 100,000,000 Class B shares authorized, 27,390,397 and 26,913,579 shares issued and outstanding, respectively; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of September 30, 2022 and as of December 31, 2021		2,753			2,620
Additional paid-in capital		2,133,614			2,054,275
Accumulated other comprehensive loss		(31,056	)		(6,353	)
Accumulated deficit		(1,020,865	)		(811,284	)
Total American Well Corporation stockholders’ equity		1,084,446			1,239,258
Non-controlling interest		20,403			21,617
Total stockholders’ equity		1,104,849			1,260,875
Total liabilities and stockholders’ equity	$	1,231,774		$	1,445,836

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Revenue
($729, $698, $3,106 and $11,005 from related parties, respectively)	$	69,209		$	62,223		$	197,957		$	180,039
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets		41,507			35,184		$	114,769			104,778
Research and development		36,254			27,399		$	110,802			72,817
Sales and marketing		18,493			16,370		$	58,368			44,891
General and administrative		37,682			34,380		$	105,309			79,946
Depreciation and amortization expense		6,397			4,340		$	19,719			9,330
Total costs and operating expenses		140,333			117,673			408,967			311,762
Loss from operations		(71,124	)		(55,450	)		(211,010	)		(131,723	)
Interest income and other (expense) income, net		1,237			(382	)	$	2,109			(97	)
Loss before expense from income taxes and loss from equity method investment		(69,887	)		(55,832	)		(208,901	)		(131,820	)
Benefit (Expense) from income taxes		(95	)		5,454		$	(224	)		5,042
Loss from equity method investment		(593	)		(554	)	$	(1,355	)		(2,095	)
Net loss		(70,575	)		(50,932	)		(210,480	)		(128,873	)
Net loss attributable to non-controlling interest		(491	)		562		$	(1,214	)		(332	)
Net loss attributable to American Well Corporation	$	(70,084	)	$	(51,494	)	$	(209,266	)	$	(128,541	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.25	)	$	(0.20	)	$	(0.77	)	$	(0.51	)
Weighted-average common shares outstanding, basic and diluted		277,389,730			257,283,961			272,846,985			250,115,414
Net loss	$	(70,575	)	$	(50,932	)	$	(210,480	)	$	(128,873	)
Other comprehensive loss, net of tax:
Unrealized gain (loss) on available-for-sale investments		1,002			0			(360	)		(85	)
Foreign currency translation		(11,213	)		(2,377	)		(24,343	)		(2,449	)
Comprehensive loss		(80,786	)		(53,309	)		(235,183	)		(131,407	)
Less: Comprehensive (loss) income attributable to non-controlling interest		(491	)		562			(1,214	)		(332	)
Comprehensive loss attributable to American Well Corporation	$	(80,295	)	$	(53,871	)	$	(233,969	)	$	(131,075	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)


	Common Stock						Additional Paid-In			Accumulated Other Comprehensive			Accumulated			American Well Corporation Stockholders’			Noncontrolling			Total Stockholders’
	Shares			Amount			Capital			Loss			Deficit			Equity			Interest			Equity
Balances as of January 1, 2022		261,871,587		$	2,620		$	2,054,275		$	(6,353	)	$	(811,284	)	$	1,239,258		$	21,617		$	1,260,875
Exercise of common stock options		976,644			10			2,455			—			—			2,465			—			2,465
Vesting of restricted stock units		1,398,305			14			(14	)		—			—			—			—			—
Issuance of stock under employee stock purchase plan		425,114			4			1,497			—			—			1,501			—			1,501
Issuance of common stock related to Conversa earn-out settlement		1,020,964			10			4,288			—			—			4,298			—			4,298
Stock-based compensation expense		—			—			12,085			—			—			12,085			—			12,085
Capital contributed by selling shareholders of acquired businesses		—			—			2,019			—			—			2,019			—			2,019
Currency translation adjustment		—			—			—			(2,951	)		—			(2,951	)		—			(2,951	)
Unrealized losses on available-for-sale securities, net of tax		—			—			—			(1,251	)		—			(1,251	)		—			(1,251	)
Net loss		—			—			—			—			(70,037	)		(70,037	)		(216	)		(70,253	)
Balances as of March 31, 2022		265,692,614			2,658			2,076,605			(10,555	)		(881,321	)		1,187,387			21,401			1,208,788
Exercise of common stock options		1,083,571			10			1,916			—			—			1,926			—			1,926
Vesting of restricted stock units		1,606,976			16			(16	)		—			—			—			—			—
Issuance of common stock related to SilverCloud earn-out settlement		4,959,856			50			12,895			—			—			12,945			—			12,945
Receipt of Section 16(b) disgorgement		—			—			295			—			—			295			—			295
Stock-based compensation expense		—			—			14,907			—			—			14,907			—			14,907
Capital contributed by selling shareholders of acquired businesses		—			—			1,974			—			—			1,974			—			1,974
Currency translation adjustment		—			—			—			(10,179	)		—			(10,179	)		—			(10,179	)
Unrealized losses on available-for-sale securities, net of tax		—			—			—			(111	)		—			(111	)		—			(111	)
Net loss		—			—			—			—			(69,145	)		(69,145	)		(507	)		(69,652	)
Balances as of June 30, 2022		273,343,017		$	2,734		$	2,108,576		$	(20,845	)	$	(950,466	)	$	1,139,999		$	20,894		$	1,160,893
Exercise of common stock options		464,622			5			853			—			—			858			—			858
Vesting of restricted stock units		1,249,647			12			(12	)		—			—			—			—			—
Shares withheld related to net share settlement and retired treasury stock in 2022		(85,002	)		(1	)		(44	)		—			(315	)		(360	)		—			(360	)
Issuance of stock under employee stock purchase plan		278,034			3			999			—			—			1,002			—			1,002
Stock-based compensation expense		—			—			21,312			—			—			21,312			—			21,312
Capital contributed by selling shareholders of acquired businesses		—			—			1,930			—			—			1,930			—			1,930
Currency translation adjustment		—			—			—			(11,213	)		—			(11,213	)		—			(11,213	)
Unrealized losses on available-for-sale securities, net of tax		—			—			—			1,002			—			1,002			—			1,002
Net loss		—			—			—			—			(70,084	)		(70,084	)		(491	)		(70,575	)
Balances as of September 30, 2022		275,250,318		$	2,753		$	2,133,614		$	(31,056	)	$	(1,020,865	)	$	1,084,446		$	20,403		$	1,104,849

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)


	Common Stock						Treasury			Additional Paid-In			Accumulated Other Comprehensive			Accumulated			American Well Corporation Stockholders’			Noncontrolling			Total Stockholders’
	Shares			Amount			Stock			Capital			Income (Loss)			Deficit			Equity			Interest			Equity
Balances as of January 1, 2021		235,604,105		$	2,357		$	(37,568	)	$	1,841,405		$	297		$	(582,359	)	$	1,224,132		$	22,065		$	1,246,197
Exercise of common stock options		3,474,375			34			—			10,096			—			—			10,130			—			10,130
Vesting of restricted stock units		853,842			9			—			(9	)		—			—			—			—			—
Retirement of treasury stock purchased in 2020		—			—			37,568			(15	)		—			(37,553	)		—			—			—
Shares withheld related to net share settlement and retired treasury stock in 2021		(402,060	)		(4	)		—			4			—			(9,771	)		(9,771	)		—			(9,771	)
Stock-based compensation expense		—			—			—			8,642			—			—			8,642			—			8,642
Currency translation adjustment		—			—			—			—			(52	)		—			(52	)		—			(52	)
Unrealized gains on available-for-sale securities, net of tax		—			—			—			—			34			—			34			—			34
Net loss		—			—			—			—			—			(39,188	)		(39,188	)		(617	)		(39,805	)
Balances as of March 31, 2021		239,530,262			2,396			—			1,860,123			279			(668,871	)		1,193,927			21,448			1,215,375
Exercise of common stock options		1,812,491			18			—			6,656			—			—			6,674			—			6,674
Vesting of restricted stock units		844,900			9			—			(9	)		—			—			—			—			—
Shares withheld related to net share settlement and retired treasury stock in 2021		(68,750	)		(1	)		—			1			—			(1,857	)		(1,857	)		—			(1,857	)
Stock-based compensation expense		—			—			—			10,726			—			—			10,726			—			10,726
Currency translation adjustment		—			—			—			—			(20	)		—			(20	)		—			(20	)
Unrealized gains on available-for-sale securities, net of tax		—			—			—			—			(119	)		—			(119	)		—			(119	)
Net loss		—			—			—			—			—			(37,859	)		(37,859	)		(277	)		(38,136	)
Balances as of June 30, 2021		242,118,903			2,422			—			1,877,497			140			(708,587	)		1,171,472			21,171			1,192,643
Exercise of common stock options		491,598			5			—			1,872			—			—			1,877			—			1,877
Vesting of restricted stock units		3,989,239			40			—			(40	)		—			—			—			—			—
Shares withheld related to net share settlement and retired treasury stock in 2021		(211,494	)		(2	)		—			2			—			(2,360	)		(2,360	)		—			(2,360	)
Issuance of stock under employee stock purchase plan		178,021			2			—			1,597			—			—			1,599			—			1,599
Issuance of common stock in acquisitions		12,798,992			128			—			143,979			—			—			144,107			—			144,107
Stock-based compensation expense		—			—			—			12,388			—			—			12,388			—			12,388
Capital contributed by selling shareholders of acquired businesses		—			—			—			717			—			—			717			—			717
Currency translation adjustment		—			—			—			—			(2,377	)		—			(2,377	)		—			(2,377	)
Net loss		—			—			—			—			—			(51,494	)		(51,494	)		562			(50,932	)
Balances as of September 30, 2021		259,365,259		$	2,595		$	—		$	2,038,012		$	(2,237	)	$	(762,441	)	$	1,275,929		$	21,733		$	1,297,662

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMERICAN WELL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share amounts)

(unaudited)


	Nine Months Ended September 30,
	2022			2021
Cash flows from operating activities:
Net loss	$	(210,480	)	$	(128,873	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		19,543			9,330
Provisions for credit losses		63			401
Amortization of deferred contract acquisition costs		1,295			1,254
Amortization of deferred contract fulfillment costs		452			535
Accertion of contingent consideration		—			600
Noncash compensation costs incurred by selling shareholders		5,923			717
Stock-based compensation expense		48,419			31,756
Loss on equity method investment		1,355			2,095
Deferred income taxes		(1,390	)		(4,184	)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable		4,796			11,325
Inventories		(439	)		28
Deferred contract acquisition costs		(2,035	)		(1,053	)
Prepaid expenses and other current assets		(924	)		946
Other assets		(276	)		319
Accounts payable		(5,797	)		(1,332	)
Accrued expenses and other current liabilities		1,166			(1,564	)
Other long-term liabilities		(25	)		(1,784	)
Deferred revenue		(18,023	)		(17,130	)
Net cash used in operating activities		(156,377	)		(96,614	)
Cash flows from investing activities:
Purchases of property and equipment		(2	)		(221	)
Investment in less than majority owned joint venture		(1,960	)		(2,548	)
Purchases of investments		(499,223	)		—
Proceeds from sales and maturities of investments		249,855			100,000
Acquisitions of business, net of cash acquired		—			(156,526	)
Net cash used in and provided by investing activities		(251,330	)		(59,295	)
Cash flows from financing activities:
Proceeds from exercise of common stock options		5,323			18,539
Proceeds from employee stock purchase plan		2,503			1,599
Payments for the purchase of treasury stock		(360	)		(13,988	)
Payment of deferred offering costs		—			(1,613	)
Proceeds from Section 16(b) disgorgement		295			—
Payment of contingent consideration		(11,790	)		—
Net cash used in and provided by financing activities		(4,029	)		4,537
Effect of exchange rates changes on cash, cash equivalents, and restricted cash		(2,079	)		(142	)
Net decrease in cash, cash equivalents, and restricted cash		(413,815	)		(151,514	)
Cash, cash equivalents, and restricted cash at beginning of period		747,211			942,711
Cash, cash equivalents, and restricted cash at end of period	$	333,396		$	791,197
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents		332,601			790,402
Restricted cash		795			795
Total cash, cash equivalents, and restricted cash at end of period	$	333,396		$	791,197
Supplemental disclosure of cash flow information:
Cash (refunded) paid for income taxes	$	1,167		$	1,414
Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accrued expenses and accounts payable	$	—		$	312
Issuance of common stock in settlement of earnout	$	17,243		$	—
Receivable related to exercise of common stock options	$	—		$	142

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMERICAN WELL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(unaudited)

1. Organization and Description of Business

Description of Business

American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders. The Company empowers our clients with the core technology and services necessary to successfully develop and distribute virtual care programs that meet their strategic, operational, financial and clinical objectives under their own brands.

Acquisitions

On August 9, 2021 and August 27, 2021, the Company completed the acquisitions of Conversa Health Inc. (“Conversa”) and SilverCloud Health Holdings, Inc. (“SilverCloud”), respectively (together, the “Acquisitions”). Conversa is a leader in automated virtual healthcare. SilverCloud is a leading digital mental health platform. See Note 7 “Business Combinations”.

Liquidity and Capital Resources

The Company expects that its cash, cash equivalents and investments balance as of September 30, 2022 of $581,609 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

2. Summary of Significant Accounting Policies

There have been no material changes to the significant accounting policies described in the Company’s Form 10-K for the fiscal year ended December 31, 2021, that have had a material impact on the consolidated financial statements and related notes.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and nine months ended September 30, 2022 are not necessarily indicative of results for the full 2022 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K.

The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation.

The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.

For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.

Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions.

Segment Information

The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.

Variable Interest Entities

The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.

The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $30,171 and $1,587, respectively, as of September 30, 2022 and $29,770 and $1,485, respectively as of December 31, 2021.

Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $17,296 and $18,356 for the three months ended September 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended September 30, 2022 and 2021. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $53,088 and $53,511 for the nine months ended September 30, 2022 and 2021, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the nine months ended September 30, 2022 and 2021.

Investment in Minority Owned Joint Venture

The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities.

In 2020 the Company contributed $2,940 as its initial investment for a 49% interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $11,800 in two phases, which is yet to be defined. During the three months ended March 31, 2021, the Company made a capital contribution of $2,548, related to a portion of the phase one capital commitment. In April 2022 the Company made a capital contribution of $1,960 related to a portion of the phase one capital commitment.

For the three months ended September 30, 2022 and 2021, the Company recognized a loss of $593 and $554 as its proportionate share of the joint venture’s results of operations, respectively. For the nine months ended September 30, 2022 and 2021, the Company recognized a loss of $1,355 and $2,095, respectively. Accordingly, the carrying value of the equity method investment as of September 30, 2022 and December 31, 2021 was $773 and $168, respectively.

Concentrations of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of September 30, 2022 and December 31, 2021, one customer accounted for 21% and 19% of outstanding accounts receivable, respectively.

During the three months ended September 30, 2022 and 2021, sales to one customer represented 22% and 26% of the Company’s total revenue, respectively. During the nine months ended September 30, 2022 and 2021, sales to one customer (which was a related party during the 2021 period) represented 24% and 25% of the Company’s total revenue, respectively.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions and clarifying and amending existing guidance. The guidance was adopted effective January 1, 2021 and did not have a material impact on the condensed consolidated financial statements and disclosures.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. The guidance was adopted effective July 1, 2021 and impacted the accounting of acquired deferred revenue for the Conversa and SilverCloud acquisitions that occurred in August 2021.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (‘‘ASU 2016-13’’), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes may result in earlier recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which narrowed the scope and changed the effective date for non-public entities for ASU 2016-13. The FASB subsequently issued supplemental guidance within ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (‘‘ASU 2019-05’’). ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. The Company adopted ASU 2016-13 and the related clarifications in 2021. The adoption did not have a material effect on the Company’s consolidated financial statements.

3. Revenue

The following table presents the Company’s revenues disaggregated by revenue source:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Platform subscription	$	31,912	$	26,736	$	90,195	$	78,112
Visits		28,807		30,042		89,293		85,395
Other		8,490		5,445		18,469		16,532
Total Revenue	$	69,209	$	62,223	$	197,957	$	180,039

Accounts Receivable, Net

Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Changes in the allowance for credit losses were as follows:


	Nine Months Ended September 30, 2022			Year Ended December 31, 2021
Allowance for credit losses, beginning of the period	$	1,809		$	1,556
Provisions		63			714
Write-offs		(304	)		(461	)
Allowance for credit losses, end of the period	$	1,568		$	1,809

The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the customer. The amount of unbilled accounts receivable included within accounts receivable on the consolidated balance sheet was $3,292 and $5,697 as of September 30, 2022 and December 31, 2021, respectively. The amount of unbilled accounts receivable included within other assets on the consolidated balance sheet was zero as of September 30, 2022 and $781 as of December 31, 2021, respectively.

Deferred Revenue

Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three months ended September 30, 2022 and 2021, the Company recognized revenue of $9,368 and $16,912, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. For the nine months ended September 30, 2022 and 2021, the Company recognized revenue of $49,360 and $56,085, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented.

Changes in the Company’s deferred revenue balance for the nine months ended September 30, 2022 and December 31, 2021 were as follows:


	Nine Months Ended September 30, 2022			Year Ended December 31, 2021
Total deferred revenue, beginning of the period	$	75,896		$	74,800
Additions		75,549			123,717
Recognized		(94,380	)		(122,621	)
Total deferred revenue, end of the period	$	57,065		$	75,896
Current deferred revenue		50,151			68,841
Non-current deferred revenue		6,914			7,055
Total	$	57,065		$	75,896

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2022 and December 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $171,781 and $219,893, respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years.

As it pertains to the September 30, 2022 amount, the Company expects to recognize 44% of the transaction price in the 12 month period ended September 30, 2023, in its condensed consolidated statement of operations and comprehensive loss with the remainder recognized thereafter.

4. National Telehealth Network

In 2012, the Company and an affiliate of Anthem, Inc. (now doing business as Elevance Health) formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significant influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015.

On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50%. The Company also obtained the right to elect the Chairman of NTN, who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s condensed consolidated financial statements. However, because the Company owns less than 100% of NTN, the Company recognizes net loss attributable to non-controlling interest in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party.

The proportionate share of the (income)/loss attributed to the non-controlling interest amounted to $491 and $(562) for the three months ended September 30, 2022 and 2021, respectively. The proportionate share of the loss attributed to the non-controlling interest amounted to $1,214 and $332 for the nine months ended September 30, 2022 and 2021, respectively.

The carrying value of the non-controlling interest was $20,403 and $21,617 as of September 30, 2022 and December 31, 2021, respectively.

5. Fair Value Measurements

Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	September 30, 2022
	Level 1		Level 2		Level 3		Total
Money market funds	$	243,538	$	—	$	—	$	243,538
U.S government securities		—		249,008		—	$	249,008
Total financial assets:	$	243,538	$	249,008	$	—	$	492,546


	December 31, 2021
	Level 1		Level 2		Level 3		Total
Money market funds	$	671,107	$	—	$	—	$	671,107
Total financial assets:	$	671,107	$	—	$	—	$	671,107
Contingent consideration	$	—	$	—	$	16,450	$	16,450
Total financial liabilities:	$	—	$	—	$	16,450	$	16,450

The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data.

The Company has classified its net liability for contingent earnout considerations relating to the Acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included the Monte Carlo method that uses key assumptions to model future revenue and costs of goods sold projections. A description of the Acquisitions is included within Note 7. The contingent earnout payments for each acquisition are based on the achievement of certain revenue thresholds. During the nine months ended September 30, 2022 the fair value of the contingent earnout consideration decreased due to the Company signing an amendment to the agreement accelerating the determination of the Conversa revenue earn-out as of March 31, 2022 that resulted in the issuance of 1,020,964 shares of Class A Common Stock, and signing an amendment to the agreement accelerating the determination of the SilverCloud revenue earn-out as of May 11, 2022 that resulted in the issuance of 4,959,856 shares of Class A Common Stock, which resulted in a net accretion to the contingent considerations of $793.


	Nine Months Ended September 30, 2022
Beginning Balance as of January 1	$	16,450
Accretion of contingent consideration		793
Fair value adjustment		—
Earned amount issued to shareholders in Class A Common Stock		(17,243	)
Ending Balance	$	—

During the nine months ended September 30, 2022, there were no transfers between fair value measurement levels.

6. Investments

As of September 30, 2022 and December 31, 2021, the fair value of the Company’s investments by type of security was as follows:


	September 30, 2022
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Assets:
U.S government securities	$	249,368		—	$	(360	)	$	249,008
	$	249,368	$	—	$	(360	)	$	249,008

December 31, 2021

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair Value

Assets:

U.S government securities

—

—

—

—

—

—

—

—

7. Business Combinations

On August 27, 2021, the Company completed the acquisition of SilverCloud through a merger in which SilverCloud became a wholly-owned subsidiary of the Company. The cash consideration paid was $105,195 net of cash acquired of $12,239. The stock consideration was comprised of 8.1 million shares of the Company’s Class A common stock valued at $85,571, and escrow share consideration of $6,376. SilverCloud is a leading digital mental health platform. The Company is obligated to pay an earn-out of up to $40,000 contingent upon SilverCloud achieving certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $29,360. The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. The Company signed an amendment to the agreement accelerating the determination of the SilverCloud revenue earn-out as of May 11, 2022, which resulted in the issuance of 4,959,856 shares of Class A Common Stock. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $4,854 which included transaction costs from financial and legal advisors and other transaction related fees and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses.

On August 9, 2021, the Company completed the acquisition of Conversa through a merger in which Conversa became a wholly-owned subsidiary of the Company. The cash consideration paid was $51,331 net of cash acquired of $9,735. The stock consideration was comprised of 4.7 million shares of the Company’s Class A common stock valued at $52,160. Conversa is a leader in automated virtual healthcare. The Company is obligated to pay an earn-out of up to $30,000 contingent upon Conversa achieving certain integration thresholds in the first quarter of 2022, and certain revenue thresholds for the year ending December 31, 2022. The Company estimated the fair value of the contingent consideration as of the acquisition date to be $15,230. The contingent consideration is subject to remeasurement at each reporting date until December 31, 2022, with the remeasurement adjustment reported in the consolidated statement of operations and comprehensive loss. The integration milestone was achieved in December 2021 and $15,000 was paid in January 2022. The Company signed an amendment to the agreement accelerating the determination of the Conversa revenue earn-out as of March 31, 2022, which resulted in the issuance of 1,020,964 shares of Class A Common Stock. The acquisition was considered a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $2,435 which included transaction costs from financial and legal advisors and other transaction related fees and were recognized as incurred in the Company’s consolidated statement of operations and comprehensive loss in general and administrative expenses.

The Acquisitions were accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and the liabilities assumed be recognized at their fair values as of the acquisition date. The results of the Acquisitions were integrated within the consolidated financial statements commencing on the aforementioned acquisition dates. Actual revenue and losses of the Acquisitions since the acquisition date as well as pro forma combined results of operations for the Acquisitions have not been presented because the effect of the Acquisitions was not material to the Company’s consolidated financial results for the periods presented.

The following table summarizes the fair value estimates of the assets acquired and liabilities assumed for the SilverCloud and Conversa acquisitions at the respective acquisition dates. The Company, with the assistance of a third-party valuation expert, estimated the fair value of the acquired tangible and intangible assets with significant estimates such as revenue projections. In the third quarter of 2022, the Company recorded a $522 decrease in goodwill related to the assessment of the tax attributes of the business combination for SilverCloud. The allocation of the consideration transferred to the assets acquired and liabilities assumed for the Acquisitions is final.

Identifiable assets acquired and liabilities assumed:


	SilverCloud			Conversa Health
Purchase consideration:
Cash consideration, net of cash acquired	$	105,195		$	51,331
Stock consideration		85,571			52,160
Contingent consideration		29,360			15,230
Escrow share consideration		6,376
Working capital adjustment		(300	)		(127	)
Total consideration transferred	$	226,202		$	118,594

Allocation of consideration transferred:
Accounts receivable	$	2,630		$	3,651
Identifiable intangible assets		78,146			34,700
Other assets		491			4,604
Total assets acquired		81,267			42,955
Current liabilities		2,155			8,463
Deferred revenue		5,813			4,655
Other long-term liabilities		11,035			115
Total liabilities assumed		19,003			13,233
Goodwill	$	163,938		$	88,872
	$	226,202		$	118,594

The amount allocated to goodwill reflects the benefits the Company expects to realize from post-acquisition cross selling opportunities from integrating customer relationships and from the growth of the respective acquisitions’ operations.

The following are the identifiable intangible assets acquired in the Acquisitions and their respective weighted average useful lives, as determined based on initial valuations. The estimated fair value of the Technology and Tradename was determined using a relief from royalty method and the estimated fair value of the Customer relationships was determined using the excess earnings method:


	SilverCloud		Weighted Average Life (Years)		Conversa Health		Weighted Average Life (Years)
Technology	$	34,996		5.0	$	20,400		5.0
Tradename		10,800		7.0		4,200		5.0
Customer relationships		32,350		10.0		10,100		10.0
Total	$	78,146			$	34,700

8. Goodwill and Intangible Assets

Goodwill consisted of the following:


	Nine Months Ended September 30, 2022
Beginning Balance as of January 1	$	442,761
Goodwill acquired		—
Purchase accounting adjustment		(522	)
Currency translation adjustments		(17,043	)
Ending Balance	$	425,196

Identified intangible assets consisted of the following:


	Gross Amount		Accumulated Amortization			Carrying Value		Weighted Average Remaining Life
September 30, 2022
Customer relationships	$	79,445	$	(22,805	)	$	56,640		7.6
Contractor relationships		535		(278	)		257		6.3
Tradename		13,002		(2,239	)		10,763		5.2
Technology		86,328		(26,697	)		59,631		4.5
	$	179,310	$	(52,019	)	$	127,291

	Gross Amount		Accumulated Amortization			Carrying Value		Weighted Average Remaining Life
December 31, 2021
Customer relationships	$	81,053	$	(16,842	)	$	64,211		8.2
Contractor relationships		535		(247	)		288		7.0
Trade name		14,435		(706	)		13,729		5.8
Technology		90,464		(16,283	)		74,181		5.0
	$	186,487	$	(34,078	)	$	152,409

Amortization expense related to intangible assets for the three months ended September 30, 2022 and 2021 was $6,045 and $3,819, respectively. Amortization expense related to intangible assets for the nine months ended September 30, 2022 and 2021 was $18,559 and $7,675, respectively. Estimated future amortization expense of the identified intangible assets as of September 30, 2022, is as follows:


2022	$	5,945
2023		23,733
2024		23,749
2025		23,733
2026		19,624
Thereafter		30,507
	$	127,291

9. Accrued Expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:


	September 30, 2022		December 31, 2021
Employee compensation and benefits	$	18,360	$	21,572
Professional services		11,420		8,766
Earned contingent consideration		—		15,000
Provider services		5,872		5,473
Other		9,529		7,900
Total	$	45,181	$	58,711

10. Stockholders’ Equity

Undesignated Preferred Stock

The Company’s Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. No shares of preferred stock were issued or outstanding as of September 30, 2022 and December 31, 2021.

Common Stock

The Company’s Amended and Restated Certificate of Incorporation which authorizes capital stock of 1,000,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 200,000,000 shares of Class C common stock, par value $0.01 per share. Except for the rights noted below, each share of Class A, Class B and Class C common stock have the same rights, are equal in all respects and are treated by us as one class of shares. Each share of Class A and Class C common stock is entitled to one vote per share on all matters presented for a vote, except that Class C common stock does not have the right to vote for elections of directors. Subject to certain conditions, Class B common stock is collectively entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power), and each share of Class B common stock will be entitled to a number of votes equal to the total number of votes held by all Class B common stock divided by the total number of then outstanding shares of Class B common stock. Shares of Class B and Class C common stock will be converted into shares of Class A common stock on a one-for-one basis upon the occurrence of certain events. Shares of Class B common stock will automatically convert on the first business day (i) after the date on which the outstanding shares of Class B common stock constitutes less than 5% of the aggregate number of shares of common stock then outstanding, (ii) after the date on which neither founder is serving as an executive officer or (iii) following seven years after the date the amended and restated certificate of incorporation becomes effective, provided that, such period may, to the extent permitted by law and applicable stock exchange rules, be extended for three years upon the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of Class A common stock entitled to vote thereon, voting separately as a class. Shares of Class C common stock will be convertible at the option of the holder upon determination that a Hart-Scott-Rodino Antitrust Improvements Act (“HSR”) filing is not necessary prior to the holder’s conversion of such shares or, if required, upon expiration or termination of the HSR waiting period.

In the three and nine months ended September 30, 2022, no shares of Class B common stock were converted to Class A common stock. As of September 30, 2022, the par value of the Class A, Class B and Class C shares was $2,422, $275, and $56, respectively.


	Shares Authorized		Shares Issued		Shares Outstanding
Class A		1,000,000,000		242,304,366		242,304,366
Class B		100,000,000		27,390,397		27,390,397
Class C		200,000,000		5,555,555		5,555,555
		1,300,000,000		275,250,318		275,250,318

As of September 30, 2022 and December 31, 2021, the Company had reserved 69,899,299 and 61,989,749 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units, the vesting of performance-based market condition share awards, and the number of shares remaining available for future grant, respectively.

Stock Plans and Stock Options

The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. The 2020 Plan is administered by the board of directors with respect to awards to non-employee directors and by the compensation committee, with respect to other participants, are collectively, referred to as the plan administrator. The exercise prices, vesting and other restrictions are determined at the discretion of the plan administrator.

Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award.

Activity under the Plans is as follows:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding as of January 1, 2022		15,893,755		$	4.81		5.9	$	23,876
Granted		—			—
Forfeited		(1,779,566	)		6.13
Expired		(49,542	)		5.63
Exercised		(2,524,837	)		2.08
Outstanding as of September 30, 2022		11,539,810		$	4.81		5.7	$	6,198
Vested and expected to vest as of December 31, 2021		15,395,398		$	4.61		5.8	$	23,752
Vested and expected to vest as of September 30, 2022		11,405,421		$	5.00		5.7	$	2,823
Options exercisable as of December 31, 2021		13,407,882		$	4.38		5.5	$	23,120
Options exercisable as of September 30, 2022		10,658,813		$	4.92		5.6	$	2,826

No options were granted in the nine months ended September 30, 2022 and 2021.

Restricted Stock Units

Activity for the restricted stock units is as follows:


	Shares			Weighted Average Grant Date Fair Value
Unvested as of January 1, 2022		11,718,813		$	19.63
Granted		12,880,812			4.21
Vested		(4,254,928	)		12.04
Forfeited		(2,012,379	)		8.70
Unvested as of September 30, 2022		18,332,318		$	7.20

The total grant date fair value of RSU’s granted for the nine months ended September 30, 2022 was $54,282. Restricted stock units vest over the service period of one to four years. The aggregate intrinsic value of restricted stock units vested for the nine months ended September 30, 2022 and 2021 was $18,304 and $77,949, respectively.

Restricted Stock Units with a Market Condition

In the nine months ended September 30, 2022 the Company granted performance-based market condition share awards to certain members of the Company’s management team, which entitle these employees with the right to receive shares of common stock, upon achievement of certain market capitalization milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. The performance-based market condition share awards for management (other than the co-CEOs) consist of six tranches with six separate specified award values that become payable upon the achievement of certain market capitalization milestones, which can result in a vesting range of up to 12,275,886 shares. Also in 2022 the Company granted performance-based market condition share awards to the co-CEOs, which entitle these employees with the right to receive shares of common stock, upon achievement of certain market capitalization milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. The performance-based market condition share awards for the co-CEOs consist of eight tranches with eight separate specified award values that become payable upon the achievement of certain market capitalization milestones (subject to specified vesting caps during each of the first two years of the performance period), which can result in a vesting range of up to 7,500,000 shares for each co-CEO. As of September 30, 2022, no portion of the performance- based market condition share awards have satisfied both the applicable market capitalization milestones and the service vesting conditions and, as such, no awards have vested. These performance-based market condition share awards have a performance period of three years.


	Shares			Weighted Average Grant Date Fair Value
Unvested as of January 1, 2022		—		$	—
Granted		27,275,886			2.32
Vested		—			—
Cancelled/Forfeited		(1,568,889	)		2.62
Unvested as of September 30, 2022		25,706,997		$	2.30

The total grant-date fair value of performance-based market condition share awards granted during the nine months ended September 30, 2022 was $63,157 and no performance-based market condition share awards were granted during the nine months ended September 30, 2021.

The weighted average estimated fair value of the performance-based market condition share awards granted during the nine months ended September 30, 2022 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions:


	Nine Months Ended September 30,
	2022
Risk-free rate		2.34	%
Term to end of performance period (yrs)	3 years
Valuation date stock price	$	3.50
Expected volatility		75	%
Expected dividend yield		0	%

2020 Employee Stock Purchase Plan

During the nine months ended September 30, 2021, the Company had 178,021 issued any shares under the ESPP. During the nine months ended September 30, 2022, the Company issued 703,148 shares under the ESPP. As of September 30, 2022 4,501,960 shares remained available for issuance.

Stock-Based Compensation

Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenues	$	427	$	436	$	1,188	$	1,346
Research and development		2,750		2,173		7,631		5,851
Selling and marketing		2,045		2,033		5,144		6,022
General and administrative		16,090		7,746		34,341		18,537
Total	$	21,312	$	12,388	$	48,304	$	31,756

As of September 30, 2022, the unrecognized stock-based compensation expense related to unvested common stock-based awards was $112,729, which is expected to be recognized over a weighted-average period of 2.7 years.

11. Commitments and Contingencies

Indemnification

The Company’s arrangements generally include certain provisions for indemnifying customers against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies customers against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the customer. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through September 30, 2022 and December 31, 2021, there have been no claims under any indemnification provisions.

Litigation

From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. On September 14, 2020, the Company received a letter from Teladoc Health, Inc. ("Teladoc") alleging that certain of the Company’s cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc filed a claim against the Company related to these allegations. On June 30, 2022, the claim was dismissed pursuant to a confidential settlement between the parties. As of September 30, 2022 and December 31, 2021, the Company did not have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

12. Income Taxes

As a result of the Company’s history of net operating losses (“NOL”), the Company continues to maintain a full valuation allowance against its domestic net deferred tax assets. For the three and nine months ended September 30, 2022, the Company recognized an income tax expense of $95 and $224, primarily due to state and foreign income tax. During the three and nine months ended September 30, 2021, the Company recorded income tax benefit of $5,454 and $5,042, primarily due to a partial release of valuation allowance in the U.S resulting from the deferred tax liabilities established as part of the Acquisitions consummated during the quarter.

13. Related-Party Transactions

Philips Holding USA, Inc.

Philips Holding USA, Inc. (“Philips”) was determined to be a related party through June 2021, because a member of the Company’s board of directors was the Business Leader of Philips Population Health Management. Prior to the board member’s departure from Philips in June 2021, the Company recognized revenue of $1,658, from contracts with this customer.

Anthem Inc.

Anthem Inc. (“Anthem”) was determined to be a related party through February 2021, because a member of the Company’s board of directors served as the Vice President of Anthem. Prior to that director's departure from Anthem in February 2021 the Company recognized revenue of $7,218 from contracts with this customer.

Cleveland Clinic

Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of September 30, 2022 and December 31, 2021, the Company held total deferred revenue of $132 and $456, respectively from contracts with this customer. As of September 30, 2022 and December 31, 2021, amounts due from Cleveland Clinic were $164 and $441, respectively.

During the three months ended September 30, 2022 and 2021, the Company recognized revenue of $310 and $286, respectively, from contracts with this customer. During the nine months ended September 30, 2022 and 2021, the Company recognized revenue of $1,764 and $816, respectively, from contracts with this customer.

CCAW, JV LLC

CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the year ended December 31, 2020, the Company made an initial investment in CCAW, JV LLC of $2,940 for its less than 50% interest in the joint venture. During the nine months ended September 30, 2021, the Company made a capital contribution of $2,548, related to a portion of the phase one capital commitment. During the nine months ended September 30, 2022 the Company made a capital contribution of $1,960 related to a portion of the phase one capital commitment.

During the three months ended September 30, 2022 and 2021 the Company recognized revenue of $419 and $412 from contracts with this customer, respectively. During the nine months ended September 30, 2022 and 2021, the Company recognized revenue of $1,342 and $1,286 from contracts with this customer, respectively.

As of September 30, 2022 and December 31, 2021, the Company held total deferred revenue of $219 and $1,426, respectively, from contracts with this customer. As of September 30, 2022 and December 31, 2021, amounts due from CCAW, JV LLC were zero and $1,613.

14. Net Loss per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Numerator:
Net loss	$	(70,575	)	$	(50,932	)	$	(210,480	)	$	(128,873	)
Net loss attributable to non-controlling interest		(491	)		562			(1,214	)		(332	)
Net loss attributable to American Well Corporation	$	(70,084	)	$	(51,494	)	$	(209,266	)	$	(128,541	)
Denominator:
Weighted-average common shares outstanding —basic and diluted		277,389,730			257,283,961			272,846,985			250,115,414
Net loss per share attributable to common stockholders—basic and diluted	$	(0.25	)	$	(0.20	)	$	(0.77	)	$	(0.51	)

The Company’s potential dilutive securities, which include stock options, unvested restricted stock units and unvested performance market-based stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common

shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Unvested restricted stock units		16,178,486		7,162,432		16,178,486		7,162,432
Unvested performance market-based stock units		25,706,997		—		25,706,997		—
Options to purchase shares of common stock		11,539,810		17,002,356		11,539,810		17,002,356
		53,425,293		24,164,788		53,425,293		24,164,788

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations, including descriptions of our business plan and strategies, are forward-looking statements. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast,” or the negative of these terms, and other similar expressions, although not all forward-looking statements contain these words.

The forward-looking statements and projections are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections.

Important factors that may materially affect such forward-looking statements and projections include the following:

•

weak growth and increased volatility in the telehealth market;

•

our history of losses and the risk we may not achieve profitability;

•

inability to adapt to rapid technological changes;

•

our customers’ acceptance of the Converge platform and our ability and the costs to further develop this platform;

•

our limited number of significant clients and the risk that we may lose their business;

•

increased competition from existing and potential new participants in the healthcare industry;

•

changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry;

•

compliance with regulations concerning personally identifiable information and personal health industry;

•

slower than expected growth in patient adoption of telehealth and in platform usage by either clients or patients;

•

inability to grow our base of affiliated and non-affiliated providers sufficient to serve patient demand;

•

our ability to comply with federal and state privacy regulations and the significant liability that could result from a cybersecurity breach or our failure to comply with such regulations;

•

our ability to establish and maintain strategic relationships with third parties;

•

our ability to complete, integrate and realize the anticipated benefits of strategic acquisitions;

•

the impact of the COVID-19 pandemic on our business or on our ability to forecast our business’s financial outlook; and

•

the risk that the insurance we maintain may not fully cover all potential exposures.

The foregoing list of factors is not exhaustive and does not necessarily include all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. The information in this Quarterly Report should be read carefully in conjunction with other uncertainties and potential events described in our Form 10-K filed with the SEC on February 28, 2022 (the “Form 10-K”).

The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this Quarterly Report. Except as required by law or regulation, we do not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances

Overview

We are a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders. We empower our clients with the core technology and services necessary to successfully develop and distribute virtual care programs that meet their strategic, operational, financial and clinical objectives under their own brands. The Amwell Platform is a complete digital care delivery solution that equips our health system, health plan, government, and innovator clients with the tools to enable new models of care for their patients and members. Our scalable technology integrates with our clients’ existing offerings and clinical workflows, spanning the continuum of care and enabling care delivery across a wide variety of clinical, retail, school and home settings. Our client-focused approach drives our success as one of the largest global digital healthcare enterprise software companies. As of December 31, 2021, we powered the digital care programs of over 55 health plans, which collectively represent more than 80 million covered lives, as well as approximately 150 of the nation’s largest health systems, encompassing more than 2,000 hospitals. Since inception, we have powered over 19.1 million telehealth visits for our clients, including more than 4.7 million in the nine months ended September 30, 2022.

We believe Amwell makes digital care transformation possible for the healthcare ecosystem. The Amwell telehealth platform ("Amwell Platform") enables virtual and automated care delivery across the full healthcare continuum – from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. We support both on-demand and scheduled consultations and offer pre-packaged care modules and programs that power over 100 unique use cases today. The Amwell Platform can be fully integrated into our clients’ patient/member portals and provider workflows. Providers can launch telehealth directly from their native EHRs, with seamless integration to their payer eligibility and claims systems. Providers, patients and members can access this care through a full range of Carepoints™, including via mobile, web, phone and our proprietary carts that support multi-way video, phone or secure messaging interactions. Through our recent acquisitions of Conversa Health, Inc. (“Conversa”) and SilverCloud Health Holdings, Inc (“SilverCloud”) (together, the “August 2021 Acquisitions”), we enable automated care touchpoints, support ongoing treatment and care through digital engagements, and escalate care when needed to a live clinician. As of September 30, 2022, approximately 100,000 of our clients’ providers use the Amwell Platform to serve their patients and members. When needed, we augment and extend our clients’ clinical capabilities with Amwell Medical Group (“AMG”), a nationwide network of clinical entities with over 6,500 multi-disciplinary providers covering 50 states with 24/7/365 coverage.

Converge™ is the latest version of the Amwell Platform and is designed to be reliable, flexible, scalable, secure and fully integrated with other healthcare software systems. Converge offers state-of-the-art data architecture and video capabilities, flexibility and scalability, and a user experience focused on the needs of patients and providers. The virtual care of today has grown to encompass hybrid care models, asynchronous and automated care, remote patient monitoring, patient and provider engagement — and the flow of data that drives all of the above. Converge has been designed from the ground up with the holistic understanding that the future care of any one patient will inevitably blend a mix of physical, digital, and automated experiences.

With Converge, the digital care capabilities that health systems and health plans care about — for example virtual primary care, post-discharge follow-up, chronic condition management, remote patient monitoring — are aligned into a single digital care operating system that aggregates all of the data from these care experiences to provide real-time insight. By providing a single platform for the digital distribution of care, Converge will accelerate innovation and interoperability for health system and health plan clients as well as other healthcare innovators, who aim to offer a seamless experience for providers, patients and members.

Our Business Model

The Amwell Platform is a complete digital care delivery solution that equips our health system, health plan and innovator partners with the tools to enable new models of care for their patients and members. We sell the Amwell Platform on a subscription basis, which with our modular platform architecture allows our clients to introduce innovative digital health use cases over time, expanding our subscription revenue opportunity. To support the Amwell Platform, we offer professional services on a fee-for-service basis and a range of patient and provider access Carepoints that support hospital and home use cases and access to AMG. The combination of the Platform, services and Carepoints allows our clients to deploy telehealth solutions across their full enterprise, deepening their relationships with existing and new patients and members through improved care access and coordination, cost, and quality. Our contracts are typically three years in length but may be longer for our largest strategic customer partners.

Total subscription fees received were $31.9 million and $26.7 million for the three months ended September 30, 2022 and 2021, respectively, and $90.2 million and $78.1 million for the nine months ended September 30, 2022 and 2021, respectively.

Health Systems

For our health system customers, the Amwell Platform’s primary function is to facilitate consultations between patients and providers affiliated with the health system. Our typical contracts with health systems are mainly the platform subscription, but also include services delivered by AMG to complement the health system provider resources, services for technology integration, marketing and Carepoints. Subscription fees are recurring and are determined based on the initial forecasted number of overall consultations throughout the entire health system on the Amwell Platform and net patient revenue of the health system. Subscriptions include a maximum number of consultations that can be delivered on the platform and similar to a cellular phone plan, when consultations exceed the contractual maximum, overages result in higher subscription fees in the following annual period. As the health system expands its use of the Amwell Platform through additional modules, there is a corresponding increase in subscription fees.

To supplement a health system’s own network of healthcare providers, health systems often choose to purchase clinical services from AMG to deliver care for certain specialties such as telepsychiatry, behavioral health therapy and general urgent care, or to simply operate as backup providers on nights and weekends. AMG services are provided on a fee-for-service basis.

Health Plans

For our health plan clients, the Amwell Platform functions to expand member access to care, improve health outcomes and the member experience, and reduce costs through care coordination and the ability to contain follow-up care to a health plan’s own network. Currently, our typical health plan contract includes a recurring subscription fee based on the number of members who have access to the Amwell Platform plus additional subscription fees associated with add-on programs that extend from urgent care services to longitudinal care. As the health plan expands its offerings on the Amwell Platform through additional programs or additional covered lives, there is a corresponding increase in subscription fees.

Our health plan clients mainly purchase clinical services that leverage our AMG network. These visit consultations are charged on a fee-for-service basis and range in price based on the type of consultation and the specialty of the provider. We have also recently launched digital programs with SilverCloud, Conversa, and our third-party partners, SWORD Health and DermatologistOnCall. These programs are each priced differently, with some including recurring subscription fees and others including volume-based and visit fees.

Innovators

Amwell has a number of unique customers that use our Platform in various ways to support their products. For example, we support: (i) Philips’ sleep apnea products and programs, (ii) a joint-venture with Cleveland Clinic and Amwell, (iii) Meuhedet’s advanced, hybrid-virtual international health plan and (iv) in the future, we plan to deliver virtual care capabilities delivered through Converge to LG devices and peripheral technologies within the walls of hospitals.

Our contracts with our innovator customers vary from simple subscription fee-only contracts, where an innovator customer embeds our technology within their product, to broad subscription fee and services contracts that resemble a blend of our health system and health plan profile contracts.

Visits

Amwell’s clinical affiliate AMG has built a network of over 6,500 providers who are registered and credentialed to deliver care on the Amwell Platform. This clinical network is designed and operated in a way that allows us to meet the aggregate visit demand requirements of our health plan and health system clients, spanning a broad mix of specialties including, for example, internal medicine, Family Medicine, Psychiatry, Gynecology, Anesthesiology, Nutritionist, Sleep Medicine, Pain Management, Psychology, Pulmonology, Urology, Health Coach, Orthopedic Surgery, Case Manager, Emergency Medicine, Gastroenterology, Nephrology, Pediatrician, Lactation Consultant, Social Worker, Vascular Surgery.

AMG earns fee-for-service revenue for each episode of care delivered on the Amwell Platform by its providers with fees varying by physician specialty or clinical program. These clinical fees vary significantly from $59 to more than $800 per consultation or case based on the specialty and may require an additional module subscription, as in the case of telepsychiatry.

Fees received from AMG-related visits were $28.8 million and $30.0 million for the three months ended September 30, 2022 and 2021, respectively, and $89.3 million and $85.4 million for the nine months ended September 30, 2022 and 2021, respectively.

Services & Carepoints

We offer a full suite of paid, supporting services to our clients to enable their telehealth offerings, including professional services to facilitate telehealth implementation, workflow design, systems integration and service expansion. To help our clients promote adoption and utilization, we offer patient and provider engagement services through our internal digital engagement agency.

Our customers often deploy telemedicine through a variety of our proprietary Carepoints, which are medical carts and kiosks designed for various clinical and community settings. These Carepoints enable providers to deliver digital care into clinical care locations, such as the ED and clinics, as well as into community settings such as retail stores, community centers, employer sites, skilled nursing facilities and schools. Carepoints consist of hardware integrated into our Platform but can also be deployed independent of our software solution. Our Carepoints are designed by our product development teams and manufactured through partner and contract relationships.

Fees received from the provision of services and Carepoints were $8.5 million and $5.4 million for the three months ended September 30, 2022 and 2021, respectively, and $18.5 million and $16.5 million for the nine months ended September 30, 2022 and 2021, respectively.

Acquisitions

We have expanded and intend to continue to expand our Platform through research and development as well as the pursuit of selective acquisitions. We have completed multiple acquisitions since our inception, which we believe have expanded the channels that we serve and our distribution capabilities as well as broadening our service offering. Our acquisitions of SilverCloud and Conversa add proven longitudinal care and behavioral healthcare capabilities to our digital care enablement platform. SilverCloud is a leading digital mental health platform. Conversa is a leader in automated virtual healthcare. Acquisition costs and integration costs are an additional one time cost incurred as part of the acquisitions and investment in the future growth of the business.

Key Factors Affecting Our Performance

We believe our future growth, success and performance are dependent on many factors, including those set forth below. While these factors present significant opportunities for us, they also represent the challenges that we must successfully address in order to grow our business and improve our results of operations.

Telehealth Utilization

Telehealth utilization is a key driver of our business. A client’s overall utilization of its telehealth platform provides an important measure of the value they derive. Telehealth utilization drives our business in three important ways. First, to the extent a client succeeds with its telehealth program and sees good usage, they are more likely to renew and potentially expand their contract with us. Second, our health systems agreements typically include a certain number of visits conducted by their own providers annually and provide that as certain volume thresholds are exceeded, its annual license fees will rise to reflect this growing value. Third, to the extent that clients utilize provider services from AMG, Amwell derives revenue from clinical fees. We expect that our future revenues will be driven by the growing adoption of telehealth and our ability to maintain and grow market share within that market.

COVID-19 has dramatically accelerated telehealth adoption seen in both overall volumes and embracement of delivering higher acuity care in a virtual medium. Peak COVID-19 pandemic visit growth reflected several factors. Many patients needed assessment for respiratory or other COVID-19-like symptoms and sought to be assessed for possible referral to hospital or testing facilities. In addition, many patients, especially those with health vulnerabilities, sought to avoid going into brick and mortar facilities – and indeed our health systems’ clients preferred wherever possible to treat patients remotely at home for non-COVID-19 related ongoing healthcare needs. Finally, we saw significant expansion of reimbursement for telehealth during the COVID-19 crisis, which made telehealth more affordable for many people.

We continue to experience these levels of telehealth adoption and usage of our Platform and products. In the nine months ended September 30, 2022, our clients completed a total of 4.7 million visits on the Amwell Platform, while in the nine months ended September 30, 2021 4.3 million visits were completed. AMG providers accounted for 24% and 25% of total visits performed on the Amwell Platform during the nine months ended September 30, 2022 and 2021, respectively. We demonstrated that virtual care goes beyond urgent care pandemic needs through the increase in scheduled visits. Scheduled visits increased to 3.5 million from 3.1 million during the nine months ended September 30, 2022 and 2021, respectively.


Total Overall Quarterly Visits
Quarter Ended	Overall Visits		Performed by Customer Providers
September 30, 2022		1,450,000		75	%
June 30, 2022		1,525,000		76	%
March 31, 2022		1,775,000		78	%
December 31, 2021		1,525,000		75	%
September 30, 2021		1,425,000		75	%
June 30, 2021		1,300,000		75	%

Active Providers

An important indicator of the value of our Amwell Platform to our clients is the number of non-AMG providers that are active on the Amwell Platform. We define “Active Providers” as providers that have delivered a visit on the Amwell Platform at least once in the last 12 months. Active Providers demonstrate the prevalence of telehealth within our clients in both home and hospital environments. We believe Active Providers is a measure of our success in delivering on our mission of enabling access to care. We expect that the overall number of Active Providers will increase over time as a result of several factors:

•

the number of modules and use cases deployed within health systems

•

the adoption of telehealth by providers across the spectrum of care

•

the expansion of modules and programs through acquisitions, including Conversa Health and SilverCloud

•

the number of programs offered through health plans

•

the continued improvement in the regulatory environment for telehealth, including reimbursement for telehealth services

•

the ongoing consumerization of healthcare

We continued to experience growth in core Active Providers in the current year, in which approximately 7,000 Active Providers were added to the Amwell Platform all coming from our Health System and Health Plan customers.


Total Active Providers
Quarter Ended	Total Active Providers		Customer Providers		AMG
September 30, 2022		98,500		95,000		3,500
June 30, 2022(1)		103,500		100,000		3,500
March 31, 2022(1)		102,000		98,500		3,500
December 31, 2021		91,500		88,000		3,500
September 30, 2021		80,000		76,000		4,000
June 30, 2021		71,000		67,000		4,000

(1)

In the quarter ended September 30, 2022, we changed our methodology of calculating Active Providers as part of our efforts to account for unique providers who conduct visits on multiple platforms and products. This change resulted in an insignificant decrease in the number of active providers reported as of June 30, 2022 and March 31, 2022. The numbers calculated using the updated methodology decreased the number of active providers to 96,000 and 96,500 as of June 30, 2022 and March 31, 2022, respectively. The impact on the prior period active providers has been deemed insignificant.

Regulatory Environment

Our operations are subject to comprehensive United States federal, state and local and international regulation in the jurisdictions in which we do business. Our ability to operate profitably will depend in part upon our ability, and that of our affiliated providers, to maintain all necessary licenses and to operate in compliance with applicable laws and rules. The COVID-19 pandemic has resulted in a reduction of regulatory and reimbursement barriers for telehealth, including removing the originating site restrictions for fee for service Medicare; the expansion of Medicare and commercial reimbursement for telehealth and an easing of state licensure policies for providers. However, it is uncertain how long the relaxed policies will remain in effect, and there can be no guarantee that once the COVID-19 pandemic is over that such restrictions will not be reinstated or changed in a way that adversely affects our business.

Seasonality

Visit volumes typically follow the annual flu season, rising during quarter four and quarter one and falling in the summer months. COVID-19 has altered these historical trends as the precautions being taken to prevent the spread of COVID-19 have essentially flattened the spike traditionally experienced related to the flu season. The future impact of COVID-19 on seasonality is unknown as there could be additional surges and demand on telehealth visits. While we sell to and implement our solutions to clients year-round, we experience some seasonality in terms of when we enter into agreements with our clients and when we launch our solutions to members.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for our non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measure and the reconciliation of this non-GAAP financial measure to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.

We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest income and other income, net, (ii) tax benefit and expense, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) public offering expenses, (vi) acquisition-related expenses, (vii) litigation expenses related to the defense of our patents in the patent infringement claim filed by Teladoc and (viii) other items affecting our results that we do not view as representative of our ongoing operations, including noncash compensation costs incurred by selling shareholders and adjustments made to the contingent consideration.

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss, for the three and nine months ended September 30, 2022 and 2021:


	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands)	2022			2021			2022			2021
Net loss	$	(70,575	)	$	(50,932	)	$	(210,480	)	$	(128,873	)
Add:
Depreciation and amortization		6,397			4,340			19,719			9,330
Interest income and other (expense) income, net		(1,237	)		382			(2,109	)		97
Benefit (Expense) from income taxes		95			(5,454	)		224			(5,042	)
Stock-based compensation		21,312			12,388			48,304			31,756
Public offering expenses(1)		—			—			—			1,223
Acquisition-related expenses		—			7,419			—			8,006
Noncash expenses and contingent consideration adjustments(2)		1,930			—			6,926			—
Litigation expense		176			371			5,575			1,918
Adjusted EBITDA	$	(41,902	)	$	(31,486	)	$	(131,841	)	$	(81,585	)

(1)

Public offering expenses include non-recurring expenses incurred in relation to our secondary offering for the nine months ended September 30, 2021.

(2)

Noncash expenses and contingent consideration adjustments include, noncash compensation costs incurred by selling shareholders and adjustments made to the contingent consideration.

Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. Our public offering expenses, including legal, accounting and other professional expenses, reflect cash expenditures and we expect such expenditures to recur from time to time. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before benefit from income taxes, net loss, earnings per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

Components of Statement of Operations

Revenue

The Company has demonstrated continued revenue growth as a direct result of increasing acceptance of telehealth, our penetration of the market, and the successful launch of new or expanded products that enable broadened applications of settings for care delivered virtually. Revenue performance is reflective of the strong foundation that has been built, focused around health plans, health systems, our provider network and a consistently increasing visit base.

We generate revenues from the use of the Amwell Platform in the form of recurring subscription fees for use of our Platform, and related services and Carepoint sales. We also generate revenue from the performance of AMG patient visits.

Cost of Revenues, Excluding Amortization of Intangible Assets

Cost of revenue primarily consists of hosting fees paid to our hosting providers, costs incurred in connection with our professional services, technical and hosting support, and costs for running our affiliated provider network operations team. These costs primarily include employee-related expenses (including salaries, bonuses, benefits, stock-based compensation and travel).

Cost of revenues are primarily driven by the size of our provider network and the hosting and technical support required to service our Platform customers. Our business models are designed to be scalable and to leverage fixed costs to generate higher revenues. While we currently expect increased investments to support accelerated growth, we also expect increased efficiencies and economies of scale. Our quarterly cost of revenues as a percentage of revenues is expected to fluctuate from period to period depending on the interplay of these aforementioned factors.

Operating Expenses

Operating expenses consist of research and development, sales and marketing, and general and administrative expenses.

Research and Development Expenses

Research and development expenses include personnel and related expenses for software and hardware engineering, information technology infrastructure, security and compliance and product development (inclusive of stock-based compensation for our research and development employees). Research and development expenses also include the periodic outsourcing of similar functions to third party specialists. Due to the quarantine and isolation strategies employed by governmental authorities, health systems and health plans to deal with the COVID-19 pandemic, a significant portion of healthcare was forced to be delivered virtually. Our health plan and health system customers believe that overall utilization of telemedicine and care delivered virtually will continue to increase during and after the COVID-19 crisis. By partnering with our customers during the crisis, we understand the increased volume and additional types of care they intend to deliver virtually on the Amwell Platform. We originally expected this increase in volume, evolution and advancement of telemedicine usage to occur over the next few years but we have now adjusted our research and development strategies to match the views of our customer partners, thus accelerating the expansion of our Platform volume capacity and the development of additional functionality through new programs and modules. We have also expanded the use of offshore resources to provide more efficient rates which are designed to offset the increased research and development spend. While we have recognized an increase in the research and development expense throughout the current year, the corresponding future revenue growth is expected to result in lower expenses as a percentage of revenue. This increased spend represents an investment in a more scalable and economically beneficial solution that will properly position the Company to benefit in the long term. We believe the increase in spend is temporary and we expect to see a gradual decline during 2023.

Our research and development expenses may also fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our research and development expenses. We are accelerating our multiyear technology investment to accommodate the anticipated significant growth in market demand for increasingly broad and sophisticated telehealth enablement infrastructure following COVID-19.

Sales and Marketing Expenses

Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, travel and stock-based compensation costs for our employees engaged in sales. We expect our sales expenses to increase as we continue to invest in the expansion of our business. We expect to hire additional sales personnel and related account management and sales support personnel to properly service our growing client base and to identify and capitalize on new strategic market opportunities.

Marketing expenses consist primarily of personnel and related expenses (inclusive of stock-based compensation) for our marketing staff, including costs of communications materials that are produced to generate greater awareness and utilization of the Amwell Platform among our clients and their users. Marketing costs also include third-party independent research, participation in trade shows, brand messaging, and public relations costs.

Our sales and marketing expenses will fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our advertising and marketing expenses.

General and Administrative Expenses

General and administrative expenses include personnel and related expenses, and professional fees incurred by finance, legal, human resources, information technology, our executives, and executive administration staff. They also include stock-based compensation for employees in these departments and expenses related to auditing, consulting, legal, and corporate insurance.

We expect our general and administrative expenses to increase for the foreseeable future as we continue to grow our business. However, we expect our general and administrative expenses to decrease as a percentage of our total revenue over the next several years. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.

Depreciation and Amortization Expense

Depreciation and amortization expense includes the amortization of intangible assets and depreciation related to our fixed assets. Amortization of intangible assets consists of the amortization of acquisition-related intangible assets, which are customer relationships, contractor relationships, technology and trade names.

Interest Income and Other Income (Expense), Net

The balance of interest income and other income (expense), net, consists predominantly of interest income on our money-market and short-term investments. We did not incur material interest expenses in the period as there were no outstanding debts or notes payables.

Provision for Income Taxes

The income tax provision and benefit were primarily due to state and foreign income tax expense, and benefit related to release of the valuation allowance as a result of our acquisitions.

Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates.

Consolidated Results of Operations

The following table sets forth our summarized condensed consolidated statement of operations data for the three and nine months ended September 30, 2022 and 2021 and the dollar and percentage change between the respective periods:


	Three Months Ended September 30,												Nine Months Ended September 30,
(in thousands)	2022			2021			Change			%			2022			2021			Change			%
Revenue	$	69,209		$	62,223		$	6,986			11	%	$	197,957		$	180,039		$	17,918			10	%
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets		41,507			35,184			6,323			18	%		114,769			104,778			9,991			10	%
Research and development		36,254			27,399			8,855			32	%		110,802			72,817			37,985			52	%
Sales and marketing		18,493			16,370			2,123			13	%		58,368			44,891			13,477			30	%
General and administrative		37,682			34,380			3,302			10	%		105,309			79,946			25,363			32	%
Depreciation and amortization expense		6,397			4,340			2,057			47	%		19,719			9,330			10,389			111	%
Total costs and operating expenses		140,333			117,673			22,660			19	%		408,967			311,762			97,205			31	%
Loss from operations		(71,124	)		(55,450	)		(15,674	)		28	%		(211,010	)		(131,723	)		(79,287	)		60	%
Interest income and other (expense) income, net		1,237			(382	)		1,619			(424	)%		2,109			(97	)		2,206			(2,274	)%
Loss before expense from income taxes and loss from equity method investment		(69,887	)		(55,832	)		(14,055	)		25	%		(208,901	)		(131,820	)		(77,081	)		58	%
Benefit (Expense) from income taxes		(95	)		5,454			(5,549	)		(102	)%		(224	)		5,042			(5,266	)		(104	)%
Loss from equity method investment		(593	)		(554	)		(39	)		7	%		(1,355	)		(2,095	)		740			(35	)%
Net loss		(70,575	)		(50,932	)		(19,643	)		39	%		(210,480	)		(128,873	)		(81,607	)		63	%
Net loss attributable to non-controlling interest		(491	)		562			(1,053	)		(187	)%		(1,214	)		(332	)		(882	)		266	%
Net loss attributable to American Well Corporation	$	(70,084	)	$	(51,494	)	$	(18,590	)		36	%	$	(209,266	)	$	(128,541	)	$	(80,725	)		63	%

Revenue

For the three months ended September 30, 2022, subscription revenue increased by $5.2 million. Subscription revenue increase was driven by the expanded use of the Amwell Platform by existing customers. The increase in other revenue was related to marketing services provided for customers. These increases were partially offset by a decrease in visit revenue due to a shift in visit mix towards urgent care (which has a lower rate per visit) and away from behavioral services. This temporary shift in mix is believed to be driven by the impact of seasonal viruses as well as the Omicron variants.

For the nine months ended September 30, 2022, subscription revenue increased by $12.1 million. This was a result of new customers subscribing to the Amwell Platform and existing customers expanding their use of the Amwell Platform. In addition, visit revenue increased by $3.9 million due to increased visit volume in urgent care, primarily associated with the Omicron variant.

Costs of Revenue, Excluding Amortization of Acquired Intangible Assets

For the three months ended September 30, 2022, the increase in cost of revenue was primarily due to an increase of $0.6 million related to employee-related costs due to increased headcount. There was also an increase in marketing services provided for customers of $4.6 million.

For the nine months ended September 30, 2022, the increase in cost of revenue was primarily due to an increase of $2.8 million related to employee-related costs due to increased headcount. There was also an increase in provider costs of $0.9 million due to increased visits, increase in marketing costs of $4.0 million related to marketing services provided for customers, and an increase in $1.0 million related to the cost of hosting services.

Research and Development Expenses

For the three months ended September 30, 2022, the increase in research and development expense was primarily driven by an increase of $4.1 million in consulting services primarily for Converge and $4.4 million in employee-related costs (inclusive of stock compensation expense) due to increased headcount.

For the nine months ended September 30, 2022, the increase in research and development expense was primarily driven by an increase of $24.4 million in consulting services for Converge and $11.5 million in employee-related costs (inclusive of stock compensation expense) due to increased headcount.

Sales and Marketing Expenses

For the three months ended September 30, 2022, the increase in sales and marketing expense primarily consisted of $1.7 million in employee-related costs (inclusive of commissions and stock compensation expense) due to increased headcount. There was also an increase of $0.5 million related to meals and travel that did not occur in the prior year.

For the nine months ended September 30, 2022, the increase in sales and marketing expense primarily consisted of $6.9 million in employee-related costs (inclusive of commissions and stock compensation expense) due to increased headcount. There was also an increase in marketing expenses of $1.4 million related to conferences and company meetings that did not occur in the prior year. In addition, there was an increase in consulting expense of $2.2 million mainly related to marketing campaigns and services for system integration.

General and Administrative Expenses

For the three months ended September 30, 2022, the increase in general and administrative expense was driven by an increase related to employee-related costs (inclusive of $8.3 million of stock compensation expense) of approximately $11.0 million, due to additional equity awards granted in 2022 and headcount increase. The increase was partially offset by a decrease in consulting expense of $4.0 million as there were no acquisitions in the three months ended September 30, 2022, and two acquisitions in the three months ended September 30, 2021. There was also a decrease of $2.9 million in legal costs mainly due to the Teladoc litigation settlement in the second quarter of 2022.

For the nine months ended September 30, 2022, the increase in general and administrative expense was driven by an increase related to employee-related costs (inclusive of $15.8 million of stock compensation expense) of approximately $25.3 million, due to additional equity awards granted in 2022 and headcount increase. There was an increase of $1.6 million in system costs to enhance administrative processing. In addition, there was an increase in contingent consideration adjustments recorded of $1.0 million related to the Conversa and SilverCloud revenue earnouts. There was also a decrease of $5.0 million in consulting costs as there were no acquisitions in the nine months ended September 30, 2022, and two acquisitions in the nine months ended September 30, 2021.

Depreciation and Amortization Expense

Depreciation expense remained consistent for the three months ended September 30, 2022. Amortization expense increased by $2.2 million for the three months ended September 30, 2022. The increase in amortization was related to the intangible assets acquired in 2021.

Depreciation expense remained consistent for the nine months ended September 30, 2022. Amortization expense increased by $10.9 million nine months ended September 30, 2022. The increase in amortization was related to the intangible assets acquired in 2021.

Interest Income and Other (Expense) Income, net

For the three and nine months ended September 30, 2022 and 2021, interest income and other (expense) income, net consist entirely of interest income and gains from our cash equivalents and short-term investments.

Expense from Income Taxes

Income tax expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2022, compared to income tax benefit of $5.5 million and $5.0 million for the three and nine months ended September 30, 2021.

Loss from Equity Method Investment

The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investments in CCAW, JV LLC using the equity method of accounting.

During the three months ended September 30, 2022 and 2021, the Company recognized a loss of $0.6 million and $0.6 million, respectively, as its proportionate share of the joint venture results of operations. During the nine months ended September 30, 2022 and 2021, the Company recognized a loss of $1.4 million and $2.1 million, respectively, as its proportionate share of the joint venture results of operations.

Liquidity and Capital Resources

The following table presents a summary of our cash flow activity for the periods set forth below:


	Nine Months Ended September 30,
	2022			2021
Consolidated Statements of Cash Flows Data:
Net cash used in operating activities	$	(156,377	)	$	(96,614	)
Net cash used in and provided by investing activities		(251,330	)		(59,295	)
Net cash used in and provided by financing activities		(4,029	)		4,537
Total	$	(411,736	)	$	(151,372	)

Sources of Financing

Our principal sources of liquidity were cash, cash equivalents and short-term investments totaling $581.6 million and $746.4 million as of September 30, 2022 and December 31, 2021, respectively, which were held for a variety of growth initiatives and investments as well as working capital purposes. Our cash, cash equivalents and short-term investments are comprised of money market funds and marketable securities including U.S. Treasury bills.

As shown in the accompanying condensed consolidated financial statements, the Company incurred a loss from operations of $211.0 million and a net loss of $210.5 million for the nine months ended September 30, 2022 and had an accumulated deficit of $1,020.9 million as of September 30, 2022.

The Company has no debt as of September 30, 2022 or December 31, 2021 and expects to generate operating losses in future years.

We believe that our existing cash and cash equivalents will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months from the issuance date of the financial statements. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of consultations on our Platform, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings, and the continuing market acceptance of telehealth services. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies and intellectual property rights. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, financial condition and results of operations would be adversely affected.

Nine months ended September 30, 2022, vs. nine months ended September 30, 2021

Cash Used in Operating Activities

For the nine months ended September 30, 2022, cash used in operating activities was $156.4 million. The primary driver of this use of cash was our net loss of $210.5 million. The net loss was reflective of the investments made back into the Company (from a

technology perspective), partially offset by the overall growth of our business including expansion of business with existing clients. The net loss was partially offset by non-cash expenses of $75.7 million (primarily stock-based compensation of $48.4 million and depreciation and amortization of $19.5 million).

For the nine months ended September 30, 2021, cash used in operating activities was $96.6 million. The primary driver of this use of cash was our net loss of $128.9 million. The net loss for the year was reflective of the investments made back into the Company (from both a personnel and technology perspective), partially offset by the overall growth of our business including an increase in new clients and expansion of business with existing clients. The net loss was partially offset by non-cash expenses of $42.5 million (primarily stock-based compensation of $31.8 million and depreciation and amortization of $9.3 million).

Cash Used in Investing Activities

Cash used in investing activities was $251.3 million for the nine months ended September 30, 2022. Cash used in investing activities consisted of purchases of short-term investments of $499.2 million and $2.0 million investment in the less than majority owned joint venture, partially offset by sales and maturities of investments of $249.9 million.

Cash used in investing activities was $59.3 million for the nine months ended September 30, 2021. Cash used in investing activities consisted of $156.5 million in acquisitions of businesses, a $2.5 million investment in the CCAW, JV LLC joint venture with Cleveland Clinic and $0.2 million in the purchases of property and equipment offset by proceeds from maturities of investments of $100.0 million.

Cash Used in and Provided by Financing Activities

Cash used in financing activities for the nine months ended September 30, 2022, was $4.0 million. Cash used in financing activities consisted of $11.8 million related to the payment of the Conversa integration earnout, partially offset by $7.8 million of proceeds from the exercise of employee stock options and employee stock purchase plan.

Cash provided by financing activities for the nine months ended September 30, 2021, was $4.5 million. Cash provided by financing activities consisted of $18.5 million of proceeds from the exercise of employee stock options. These proceeds were offset by cash payments primarily for the purchase of treasury stock of $14.0 million.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We are therefore not exposed to the financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships.

Contractual Obligations and Commitments

As of September 30, 2022, there have been no material changes from the contractual obligations and commitments previously disclosed in our Form 10-K.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements and the related notes thereto are prepared in accordance with GAAP. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment evolves.

Our significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, to our condensed consolidated financial statements in our Form 10-K and Note 2, Summary of Significant Accounting Policies to our condensed

consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no significant changes to these policies during the nine months ended September 30, 2022.

Recently Issued Accounting Pronouncements Adopted

For more information on recently issued accounting pronouncements, see Note 2 to our condensed consolidated financial statements covered under Part I, Item 1 of this Quarterly Report on Form 10-Q.

New Accounting Pronouncements Not Yet Adopted

For more information on new accounting pronouncements not yet adopted, see Note 2 to our condensed consolidated financial statements covered under Part I, Item 1 in this Quarterly Report on Form 10-Q.

Item 3. Qualitative and Quantitative Disclosure about Market Risk

Interest Rate Risk

We had cash and cash equivalents totaling $332.6 million, and $746.4 million as of September 30, 2022 and December 31, 2021, respectively. The Company also held investments totaling $249.0 million as of September 30, 2022. The Company held no investments as of December 31, 2021. These amounts were primarily invested in money markets and U.S. Treasury bills. The cash and cash equivalents are held for a variety of growth and investments as well as working capital purposes. Our investments are made for capital preservation purposes. We do not enter into investments for trading or speculative purposes. All our investments are denominated in U.S. dollars.

We do not believe that an increase or decrease of 100 basis points in interest rates would have a material effect on our business, financial condition or results of operations. However, our cash equivalents are subject to market risk due to changes in interest rates. Fixed rate securities may have their market value adversely affected due to a rise in interest rates. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

Fluctuations in the value of our money market funds caused by a change in interest rates (gains or losses on the carrying value) are recorded in other income and are realized only if we sell the underlying securities.

Foreign Currency Exchange Risk

To date, a substantial majority of our revenue from customer arrangements has been denominated in U.S. dollars. We have limited operations outside the United States. As of September 30, 2022 and December 31, 2021, we had four foreign subsidiaries with functional currencies of the Euro, British pound, Australian dollars and New Israeli Shekel. As of September 30, 2021 the Company had one foreign subsidiary in Israel, the functional currency of that subsidiary is the U.S. dollar, and Company had a branch with a functional currency of the New Israeli Shekel. The activity for these entities in the nine months ended September 30, 2022 and 2021 was not considered significant. Accordingly, we believe we do not have a material exposure to foreign currency risk. We may choose to focus on international expansion, which may increase our exposure to foreign currency exchange risk in the future.

Inflation Risk

We do not believe that inflation had a material effect on our business, financial condition or results of operations in the last two years. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition or results of operations.

Item 4. Controls and Procedures

Managements Report on Internal Control over Financial Reporting

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our principal executive officers and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on

this evaluation, our principal executive officers and principal financial officer concluded that as of September 30, 2022, our disclosure controls and procedures were effective. Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, financial condition, results of operations or cash flows. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

On September 14, 2020, we received a letter from Teladoc Health, Inc. ("Teladoc") alleging that certain of our cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc filed a claim against the Company related to these allegations. On June 30, 2022, the claim was dismissed pursuant to a confidential settlement between the parties.

Item 1A. Risk Factors

Other than the risk factor set forth below, there have been no material changes to the risk factors previously disclosed in our Form 10-K. For a discussion of potential risks and uncertainties related to our Company see the information in our Form 10-K in the section entitled “Risk Factors.”

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Special Note Regarding Forward-Looking Statements” section in Part I, Item 2, of this Quarterly Report on Form 10-Q.

We may make adjustments to our historical Active Providers metrics as a result of changes in our methodology

While we believe that our Active Providers metrics are reasonable, we do not tag each provider using our platform. We base the Active Providers metrics on internal estimates that involve judgment, assumptions and sampling. We are continually seeking to improve the accuracy of our Active Providers metrics. As a result of improvements or changes in our methodology, we may make adjustments to our historical Active Providers metrics.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

There were no sales of unregistered equity securities during the quarter ended September 30, 2022.

Issuer Purchases of Equity Securities

The following table provides information about the Company’s purchases of its common stock for each month during this quarterly period covered by this report:


Period	(a) Total number of shares (or units) purchased*		(b) Average price paid per share (or unit)*		(c) Total number of shares (or units) purchased as part of publicly announced plans or programs		(d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
July 1 to July 31		68,051	$	4.25		—		—
August 1 to August 31		7,421		4.47		—		—
September 1 to September 30		9,530		3.90		—		—
Total		85,002	$	4.23		—		—

* Shares withheld to cover tax withholding obligations under the net settlement provision upon vesting of restricted stock units and exercising of options.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

The documents listed below are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).


10.1#*		Amendment No1 Employment Agreement by and between Kurt Knight and American Well Corporation, dated August 26, 2020

10.2#*		Amendment No1 Employment Agreement by and between Robert Shepardson and American Well Corporation, dated September 15, 2021

10.3#*		Amendment No1 Employment Agreement by and between Phyllis Gotlib and American Well Corporation, dated April 8, 2022

10.4*		Amendment No. 8 to the Restated Vendor Agreement dated January 1, 2022, by and among American Well Corporation and Anthem, Inc.

10.5*		Amendment No. 9 to the MSA Agreement, dated October 1, 2022, by and among American Well Corporation and Elevance Health, Inc.

10.6*		Amendment No. 10 to the Amended Restated Vendor Agreement , dated November 4, 2022, by and among American Well Corporation and Elevance Health, Inc. (Anthem, Inc.)

31.1*		Chief Executive Officers Certifications

31.2*		Chief Financial Officer Certification

32.1*		CEO Certification of Quarterly Report

32.2*		CFO Certifications of Quarterly Report

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


*	Filed herewith


#	Indicates a management contract or compensatory plan

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



			AMERICAN WELL CORPORATION

Date:	November 8, 2022	By:	/s/ Ido Schoenberg, MD
			Co-Chief Executive Officer
			(Principal Executive Officer)

Date:	November 8, 2022	By:	/s/ Roy Schoenberg, MD, MPH
			Co-Chief Executive Officer
			(Principal Executive Officer)

Date:	November 8, 2022	By:	/s/ Robert Shepardson
			Chief Financial Officer
			(Principal Financial Officer)

Date:	November 8, 2022	By:	/s/ Paul McNeice
			Vice President of Accounting
			(Principal Accounting Officer)